Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models. (27th August 2013)
- Record Type:
- Journal Article
- Title:
- Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models. (27th August 2013)
- Main Title:
- Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models
- Authors:
- Minelli, R
Occhipinti, S
Gigliotti, C L
Barrera, G
Gasco, P
Conti, L
Chiocchetti, A
Zara, G P
Fantozzi, R
Giovarelli, M
Dianzani, U
Dianzani, C - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12255-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>Solid lipid nanoparticles containing cholesteryl butyrate (cholbut SLN) can be a delivery system for the anti‐cancer drug butyrate. These nanoparticles inhibit adhesion of polymorphonuclear and tumour cells to endothelial cells and migration of tumour cells, suggesting that they may act as anti‐inflammatory and anti‐tumour agents. Here we have evaluated the effects of cholbut SLN on tumour cell growth using <italic>in vitro</italic> and <italic>in vivo</italic> models.</p> </sec> <sec id="bph12255-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>Cholbut SLNs were incubated with cultures of four tumour cell lines, and cell growth was analysed by assessing viability, clonogenic capacity and cell cycle. Effects on intracellular signalling was assessed by Western blot analysis of Akt expression. The <italic>in vivo</italic> anti‐tumour activity was measured in two models of PC‐3 cell xenografts in SCID/Beige mice.</p> </sec> <sec id="bph12255-sec-0003" sec-type="section"> <title>Key Results</title> <p>Cholbut SLN inhibited tumour cell line viability, clonogenic activity, Akt phosphorylation and cell cycle progression. In mice injected i.v. with PC3‐Luc cells and treated with cholbut SLN, . <italic>in vivo</italic> optical imaging and histological analysis showed no metastases in the<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bph12255-sec-0001" sec-type="section"> <title>Background and Purpose</title> <p>Solid lipid nanoparticles containing cholesteryl butyrate (cholbut SLN) can be a delivery system for the anti‐cancer drug butyrate. These nanoparticles inhibit adhesion of polymorphonuclear and tumour cells to endothelial cells and migration of tumour cells, suggesting that they may act as anti‐inflammatory and anti‐tumour agents. Here we have evaluated the effects of cholbut SLN on tumour cell growth using <italic>in vitro</italic> and <italic>in vivo</italic> models.</p> </sec> <sec id="bph12255-sec-0002" sec-type="section"> <title>Experimental Approach</title> <p>Cholbut SLNs were incubated with cultures of four tumour cell lines, and cell growth was analysed by assessing viability, clonogenic capacity and cell cycle. Effects on intracellular signalling was assessed by Western blot analysis of Akt expression. The <italic>in vivo</italic> anti‐tumour activity was measured in two models of PC‐3 cell xenografts in SCID/Beige mice.</p> </sec> <sec id="bph12255-sec-0003" sec-type="section"> <title>Key Results</title> <p>Cholbut SLN inhibited tumour cell line viability, clonogenic activity, Akt phosphorylation and cell cycle progression. In mice injected i.v. with PC3‐Luc cells and treated with cholbut SLN, . <italic>in vivo</italic> optical imaging and histological analysis showed no metastases in the lungs of the treated mice. In another set of mice injected s.c. with PC‐3 cells and treated with cholbut SLN when the tumour diameter reached 2 mm, analysis of the tumour dimensions showed that treatment with cholbut SLN substantially delayed tumour growth.</p> </sec> <sec id="bph12255-sec-0004" sec-type="section"> <title>Conclusion and Implications</title> <p>Cholbut SLN were effective in inhibiting tumour growth <italic>in vitro</italic> and <italic>in vivo</italic>. These effects may involve, in part, inhibition of Akt phosphorylation, which adds another mechanism to the activity of this multipotent drug.</p> </sec> </abstract> … (more)
- Is Part Of:
- British journal of pharmacology. Volume 170:Number 2(2013:Sep.)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 170:Number 2(2013:Sep.)
- Issue Display:
- Volume 170, Issue 2 (2013)
- Year:
- 2013
- Volume:
- 170
- Issue:
- 2
- Issue Sort Value:
- 2013-0170-0002-0000
- Page Start:
- 233
- Page End:
- 244
- Publication Date:
- 2013-08-27
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.12255 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3477.xml